文献速递消化、代谢与肾脏急症儿科与产科急症

药物相互作用与COVID-19患者秋水仙碱的临床耐受性:COLCORONA随机临床试验的二次分析

Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-09-03
一句话结论在COLCORONA试验的二次分析中,操作性药物相互作用分类系统3级或4级药物相互作用似乎未显著增加秋水仙碱相关不良事件风险。

该研究为COLCORONA随机双盲安慰剂对照试验的二次分析,纳入门诊COVID-19且至少1项高危特征的患者,秋水仙碱组2205例(0.5 mg每日两次×3天,后0.5 mg每日一次,共27天),安慰剂组2227例。最常见相互作用药物为瑞舒伐他汀(12%)和阿托伐他汀(10%)。校正后,无相互作用者中秋水仙碱组胃肠道不良事件OR 1.80(95%CI 1.51-2.15),有相互作用者中OR 1.68(95%CI 1.24-2.26),交互作用P=0.69;COVID-19住院或死亡复合终点交互作用P=0.80。结论认为3级或4级药物相互作用似乎未显著增加秋水仙碱相关不良事件风险。

要点

  • 门诊COVID-19高危患者中秋水仙碱0.5 mg每日两次×3天、后0.5 mg每日一次共27天,最常见相互作用药物为瑞舒伐他汀(12%)和阿托伐他汀(10%)。
  • 无药物相互作用者中秋水仙碱组胃肠道不良事件OR 1.80(95%CI 1.51-2.15),有相互作用者中OR 1.68(95%CI 1.24-2.26),交互作用P=0.69。
  • 药物相互作用状态未显著改变秋水仙碱对COVID-19住院或死亡复合终点的影响(有相互作用OR 0.91,95%CI 0.59-1.40;无相互作用OR 0.84,95%CI 0.60-1.19;交互作用P=0.80)。
  • 校正模型纳入年龄、性别、估算肾小球滤过率、糖尿病、心力衰竭和心肌梗死。
  • 结论:操作性药物相互作用分类系统3级或4级药物相互作用似乎未显著增加秋水仙碱相关不良效应风险。

适用人群与场景

  • COLCORONA试验纳入的门诊COVID-19患者,且至少具有1项高危特征。

处置流程与药物剂量

  • 秋水仙碱0.5 mg每日两次,共3天,之后0.5 mg每日一次,总疗程27天,用于门诊COVID-19且至少1项高危特征的患者。
  • 基线药物相互作用采用既往发表的专家分类(操作性药物相互作用分类系统)识别。
  • 校正年龄、性别、估算肾小球滤过率、糖尿病、心力衰竭和心肌梗死的logistic回归模型评估药物相互作用状态对随机分组与结局关联的效应修饰。

研究设计与关键结果

  • 研究类型:COLCORONA随机双盲安慰剂对照试验的二次分析;地点:巴西、加拿大、希腊、南非、西班牙和美国;时间:2020年3月23日至2021年1月20日;数据分析时间:2023年2月24日至2024年6月20日。
  • 样本量:秋水仙碱组2205例,安慰剂组2227例;中位年龄54岁(IQR 47-61),女性2389例(54%)。
  • 主要终点为治疗相关和治疗无关的严重及非严重胃肠道不良事件的复合终点;次要终点为其他不良事件及COVID-19感染导致的死亡或住院复合终点。
  • 最常见秋水仙碱药物相互作用:瑞舒伐他汀(12%)和阿托伐他汀(10%)。
  • 完全校正模型中,无药物相互作用者中秋水仙碱组任何胃肠道不良事件OR为1.80(95%CI 1.51-2.15),有药物相互作用者中OR为1.68(95%CI 1.24-2.26),交互作用P=0.69。
  • 药物相互作用状态未显著改变秋水仙碱对COVID-19住院或死亡复合终点的影响:有药物相互作用OR 0.91(95%CI 0.59-1.40),无药物相互作用OR 0.84(95%CI 0.60-1.19),交互作用P=0.80。

证据类型、等级与局限

  • 证据类型:随机双盲安慰剂对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,操作性药物相互作用分类系统3级或4级药物相互作用似乎未显著增加秋水仙碱相关不良效应风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Colchicine has many drug-drug interactions with commonly prescribed medications. Only pharmacokinetic studies have provided data on colchicine drug-drug interactions.

OBJECTIVE: To evaluate the clinical tolerability of colchicine according to the presence or absence of a drug-drug interaction.

DESIGN, SETTING, AND PARTICIPANTS: A secondary analysis of the COLCORONA trial was performed. The COLCORONA trial was a randomized, double-blind, placebo-controlled trial conducted in Brazil, Canada, Greece, South Africa, Spain, and the US between March 23, 2020, and January 20, 2021. The COLCORONA trial included ambulatory patients with COVID-19 with at least 1 high-risk characteristic and compared the effects of colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily thereafter) with placebo for 27 days. Data analysis was performed from February 24, 2023, to June 20, 2024.

EXPOSURE: In this secondary analysis, baseline medications that had interactions with colchicine were identified using a previously published expert classification.

MAIN OUTCOMES AND MEASURES: The primary outcome for this analysis was the composite of serious and nonserious treatment-related and treatment-unrelated gastrointestinal adverse events. The secondary outcomes were other adverse events and the composite of death or hospital admission due to COVID-19 infection. Logistic regression models adjusted for age, sex, estimated glomerular filtration rate, diabetes, heart failure, and myocardial infarction were assessed for effect modification of the association between the randomization arm and the outcomes of interest by drug-drug interaction status.

RESULTS: The cohort included 2205 participants in the colchicine arm and 2227 in the placebo arm (median age, 54 [IQR, 47-61] years; 2389 [54%] women). The most common colchicine drug-drug interactions were rosuvastatin (12%) and atorvastatin (10%). In fully adjusted models, the odds of any gastrointestinal adverse event were 1.80 (95% CI, 1.51-2.15) times higher in the colchicine arm than the placebo arm among people without a drug-drug interaction and 1.68 (95% CI, 1.24-2.26) times higher in the colchicine arm than the placebo arm among people with a drug-drug interaction (P = .69 for interaction). Drug-drug interaction status did not significantly modify the effect of colchicine on the composite of COVID-19 hospitalization or death (odds ratio, 0.91; 95% CI, 0.59-1.40 for drug-drug interaction and 0.84; 95% CI, 0.60-1.19 for no drug-drug interaction; P = .80 for interaction).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of the COLCORONA trial, operational classification of drug interactions system class 3 or 4 drug-drug interactions did not appear to significantly increase the risk of colchicine-related adverse effects.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04322682.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Alfehaid LS, Farah S, Omer A, et al. Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39240567. doi:10.1001/jamanetworkopen.2024.31309

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。